REFERENCES
- Ellenhorn M J, Barceloux D G. Medical Toxicology. Elsevier, New York 1988; 444
- Skillman T, Feldman J. The pharmacology of sulfonylureas. Am J Med 1981; 70: 361–372
- Jackson J, Bressler R. Clinical pharmacology of sulfonylurea hypoglycaemic agents. Drugs 1981; 22: 211–245
- Sturgess N C, Ashford M LJ, Cook D L, et al. The sulphonyl receptor may be an ATP-sensitive potassium channel. Lancet 1985; 2: 474–475
- Ferner R E, Neil H AW. Sulphonylureas and hypoglycaemia. Br Med J 1988; 296: 949–950
- Peden N, Newton R W, Feely J. Oral hypoglycaemic agents. Br Med J 1983; 286: 1564–1567
- Lebovitz H. Oral antidiabetic agents. Joslin's Diabetes Mellitus, C R Kahn, G C Weir. 13th ed., Lea & Febinger, Philadelphia 1994; 508–529
- Smits P, Thien T. Cardiovascular effects of sulphonylurea derivatives. Implications for the treatment of NIDDM?. Diabetologia 1995; 38: 116–121
- Tseng C H, Tai T Y., Feely J. Risk factor for hyperinsulinemia in chlorpropamide-treated diabetic patients: A three-year follow-up. J Formos Med Assoc 1992; 8: 770–775
- Rayman G, Santo M, Salomon F, et al. Hyperinsulinaemic hypoglycaemia due to chlorpropamide-induced nesidioblastosis. J Clin Pathol 1984; 37: 651–654
- Leibowitz G, Cerasi E. Sulphonylurea treatment of NIDDM patients with cardiovascular disease: A mixed blessing?. Diabetologia 1996; 39: 503–514
- Cleveland J C, Meldrum D R, Cain B S, et al. Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium. Circulation 1997; 96: 29–32